Outlook Therapeutics (OTLK)

• Market cap: $52.4M
• 1 day: -5.6%
• 5 days: -4.07%
• 1 month: 8.26%
• 3 months: -37.23%
• 6 months: -17.48%
• Year to date: -42.72%
• 1 year: -81.87%
• 5 years: -92.8%
• 10 years: -99.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 23